The first phase III clinical trial began in 1998.[2][3] In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.[4][5]
^Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
^Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
^Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. (October 2008). "Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer". European Journal of Cancer. 44 (15): 2178–84. doi:10.1016/j.ejca.2008.06.036. PMID18676140.
